Hyperuricemia Drug Pipeline Analysis Report 2025
Description
Hyperuricemia is a condition characterized by elevated uric acid levels in the blood, which can lead to gout and other serious complications. It accounts for a significant global health burden, with prevalence rates ranging from 2.6% to 36% in different populations. Despite the availability of treatments such as allopurinol and febuxostat, there remains a high unmet clinical need for more effective therapies. Current treatments may not adequately control uric acid levels or prevent flare-ups. The growing focus on novel hyperuricemia drug candidates, such as urate-lowering agents and uric acid transport inhibitors, is expected to drive pipeline growth and offer improved outcomes for patients in the coming years.
Report Coverage
The Hyperuricemia Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into hyperuricemia therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for hyperuricemia. The hyperuricemia report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The hyperuricemia pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with hyperuricemia treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to hyperuricemia.
Hyperuricemia Drug Pipeline Outlook
Hyperuricemia is a condition characterized by an excess of uric acid in the bloodstream. It occurs when the body either produces too much uric acid or fails to excrete enough through the kidneys. This can lead to the formation of urate crystals, causing inflammation and pain, especially in the joints, resulting in conditions like gout.
Hyperuricemia is typically treated with uric acid-lowering medications, such as allopurinol and febuxostat, which reduce uric acid production. Nonsteroidal anti-inflammatory drugs (NSAIDs) and colchicine may be used to manage flare-ups, while lifestyle changes like dietary modification and weight management play a supportive role in controlling the condition.
Hyperuricemia Epidemiology
The global prevalence of hyperuricemia varies significantly, with rates ranging from 2.6% to 36% across different populations. A 2024 study reveals that approximately 21% of adults in the United States, or 43 million individuals, are affected, while in India, the prevalence stands at 44.6%. A 2022 report indicates that in Europe, hyperuricemia affects 19.1% to 25.0% of the population, and in Japan, the prevalence is 26.8% in men and 9% in women.
Hyperuricemia – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of hyperuricemia drug candidates based on several segmentations, including:
By Phase
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phases II and III cover a significant share of the total hyperuricemia clinical trials.
Hyperuricemia – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the hyperuricemia pipeline analysis include small molecules, monoclonal antibodies, gene therapies, and enzyme replacement therapies. The hyperuricemia report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for hyperuricemia.
Hyperuricemia Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the hyperuricemia drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed hyperuricemia therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in hyperuricemia clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for hyperuricemia. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of hyperuricemia drug candidates.
HR091506 Tablets
The clinical study sponsored by Jiangsu HengRui Medicine Co., Ltd. aims to evaluate the efficacy and safety of HR091506 tablets in treating gout with hyperuricemia in adults. The Phase III study will compare HR091506 tablets with febuxostat tablets. The study is expected to be completed by June 2025, with approximately 750 participants enrolled.
Drug: Febuxostat
The Phase II/III study, sponsored by Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd, aims to evaluate the efficacy and safety of AR882 capsules in patients with primary gout and hyperuricemia. The study compares AR882 with Febuxostat tablets, focusing on serum uric acid reduction. It is expected to be completed by April 2026, with an estimated 636 participants.
Drug: IG3018
Intelligem Therapeutics Australia Pty Ltd. is sponsoring a Phase I/II clinical study, that aims to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of IG3018 tablets in subjects with hyperuricemia, with or without chronic kidney disease (CKD). The study plans to enroll around 46 participants and is expected to be completed by January 2026.
Reasons To Buy This Report
The Hyperuricemia Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for hyperuricemia. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into hyperuricemia collaborations, regulatory environments, and potential growth opportunities.
Key Questions Answered in the Hyperuricemia – Pipeline Insight Report
Acute Gout Flare Epidemiology
Global Diabetes Drugs Market
Acute Kidney Injury Drug Pipeline
Global Clinical Trials Market
Report Coverage
The Hyperuricemia Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into hyperuricemia therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for hyperuricemia. The hyperuricemia report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The hyperuricemia pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with hyperuricemia treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to hyperuricemia.
Hyperuricemia Drug Pipeline Outlook
Hyperuricemia is a condition characterized by an excess of uric acid in the bloodstream. It occurs when the body either produces too much uric acid or fails to excrete enough through the kidneys. This can lead to the formation of urate crystals, causing inflammation and pain, especially in the joints, resulting in conditions like gout.
Hyperuricemia is typically treated with uric acid-lowering medications, such as allopurinol and febuxostat, which reduce uric acid production. Nonsteroidal anti-inflammatory drugs (NSAIDs) and colchicine may be used to manage flare-ups, while lifestyle changes like dietary modification and weight management play a supportive role in controlling the condition.
Hyperuricemia Epidemiology
The global prevalence of hyperuricemia varies significantly, with rates ranging from 2.6% to 36% across different populations. A 2024 study reveals that approximately 21% of adults in the United States, or 43 million individuals, are affected, while in India, the prevalence stands at 44.6%. A 2022 report indicates that in Europe, hyperuricemia affects 19.1% to 25.0% of the population, and in Japan, the prevalence is 26.8% in men and 9% in women.
Hyperuricemia – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of hyperuricemia drug candidates based on several segmentations, including:
By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- Small Molecules
- Monoclonal Antibodies
- Gene Therapies
- Enzyme Replacement Therapies
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phases II and III cover a significant share of the total hyperuricemia clinical trials.
Hyperuricemia – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the hyperuricemia pipeline analysis include small molecules, monoclonal antibodies, gene therapies, and enzyme replacement therapies. The hyperuricemia report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for hyperuricemia.
Hyperuricemia Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the hyperuricemia drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed hyperuricemia therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in hyperuricemia clinical trials:
- Shenyang Sunshine Pharmaceutical Co., Ltd.
- Innovent Biologics (Suzhou) Co. Ltd.
- Shanton Pharma Pte. Ltd.
- Intelligem Therapeutics Australia Pty Ltd.
- Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd.
- Jiangsu HengRui Medicine Co., Ltd.
- LG Chem
- Arthrosi Therapeutics
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for hyperuricemia. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of hyperuricemia drug candidates.
HR091506 Tablets
The clinical study sponsored by Jiangsu HengRui Medicine Co., Ltd. aims to evaluate the efficacy and safety of HR091506 tablets in treating gout with hyperuricemia in adults. The Phase III study will compare HR091506 tablets with febuxostat tablets. The study is expected to be completed by June 2025, with approximately 750 participants enrolled.
Drug: Febuxostat
The Phase II/III study, sponsored by Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd, aims to evaluate the efficacy and safety of AR882 capsules in patients with primary gout and hyperuricemia. The study compares AR882 with Febuxostat tablets, focusing on serum uric acid reduction. It is expected to be completed by April 2026, with an estimated 636 participants.
Drug: IG3018
Intelligem Therapeutics Australia Pty Ltd. is sponsoring a Phase I/II clinical study, that aims to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of IG3018 tablets in subjects with hyperuricemia, with or without chronic kidney disease (CKD). The study plans to enroll around 46 participants and is expected to be completed by January 2026.
Reasons To Buy This Report
The Hyperuricemia Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for hyperuricemia. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into hyperuricemia collaborations, regulatory environments, and potential growth opportunities.
Key Questions Answered in the Hyperuricemia – Pipeline Insight Report
- Which companies/institutions are leading the hyperuricemia drug development?
- What is the efficacy and safety profile of hyperuricemia pipeline drugs?
- Which company is leading the hyperuricemia pipeline development activities?
- What is the current hyperuricemia commercial assessment?
- What are the opportunities and challenges present in the hyperuricemia drug pipeline landscape?
- What is the efficacy and safety profile of hyperuricemia pipeline drugs?
- Which company is conducting major trials for hyperuricemia drugs?
- Which companies/institutions are involved in hyperuricemia collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in hyperuricemia?
Acute Gout Flare Epidemiology
Global Diabetes Drugs Market
Acute Kidney Injury Drug Pipeline
Global Clinical Trials Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Hyperuricemia
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile: Hyperuricemia
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Hyperuricemia: Epidemiology Snapshot
- 5.1 Hyperuricemia Incidence by Key Markets
- 5.2 Hyperuricemia – Patients Seeking Treatment in Key Markets
- 6 Hyperuricemia: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Hyperuricemia: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Hyperuricemia, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Hyperuricemia Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Hyperuricemia Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Drug: HR091506 Tablets
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Drug: Febuxostat
- 10.2.3 Other Drugs
- 11 Hyperuricemia Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Drug: IG3018
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Other Drugs
- 12 Hyperuricemia Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Drug: Pegylated Recombinant Candida Utilis Uricase for Injection
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Other Drugs
- 13 Hyperuricemia Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug 1
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 Hyperuricemia, Key Drug Pipeline Companies
- 14.1 Shenyang Sunshine Pharmaceutical Co., Ltd.
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Innovent Biologics (Suzhou) Co. Ltd.
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Shanton Pharma Pte. Ltd.
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Intelligem Therapeutics Australia Pty Ltd.
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd.
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 Jiangsu HengRui Medicine Co., Ltd.
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 14.7 LG Chem
- 14.7.1 Company Snapshot
- 14.7.2 Pipeline Product Portfolio
- 14.7.3 Financial Analysis
- 14.7.4 Recent News and Developments
- 14.8 Arthrosi Therapeutics
- 14.8.1 Company Snapshot
- 14.8.2 Pipeline Product Portfolio
- 14.8.3 Financial Analysis
- 14.8.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
